Previous research findings have indicated the downregulation of MIIP in a range of malignancies, encompassing endometrial cancer, ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer, glioma, and colon cancer (Du and Wang 2019; Hu et al. 2020; Song et al. 2003; Sun et al. 2017; Wang et al. 2016; Wen et al. 2016). This evidence concerns the gene MIIP and prostate carcinoma.